TAYSHA GENE THERAPIES INC's ticker is TSHA and the CUSIP is 877619106. A total of 40 filers reported holding TAYSHA GENE THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,562,254 | +378.1% | 810,840 | 0.0% | 0.00% | – |
| Q2 2023 | $535,965 | -17.1% | 810,840 | 0.0% | 0.00% | – |
| Q1 2023 | $646,726 | -64.7% | 810,840 | -0.0% | 0.00% | -100.0% |
| Q4 2022 | $1,833,016 | +17.1% | 811,069 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,565,000 | -48.1% | 811,069 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,017,000 | -64.4% | 811,069 | -37.6% | 0.00% | -66.7% |
| Q1 2022 | $8,480,000 | -44.4% | 1,300,668 | -0.6% | 0.00% | -40.0% |
| Q4 2021 | $15,244,000 | -37.5% | 1,308,533 | -0.1% | 0.01% | -44.4% |
| Q3 2021 | $24,396,000 | -11.9% | 1,310,210 | +0.3% | 0.01% | -18.2% |
| Q2 2021 | $27,684,000 | +21.9% | 1,305,846 | +16.7% | 0.01% | +22.2% |
| Q1 2021 | $22,719,000 | +7.1% | 1,119,169 | +40.0% | 0.01% | 0.0% |
| Q4 2020 | $21,220,000 | +18.3% | 799,529 | -0.1% | 0.01% | 0.0% |
| Q3 2020 | $17,932,000 | – | 800,520 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 2,000,000 | $53,080,000 | 57.48% |
| Octagon Capital Advisors LP | 320,440 | $8,504,000 | 2.95% |
| Alphabet Inc. | 640,882 | $17,009,000 | 0.82% |
| Casdin Capital, LLC | 820,440 | $21,774,000 | 0.64% |
| Artal Group S.A. | 1,040,882 | $27,625,000 | 0.59% |
| VR Adviser, LLC | 107,982 | $2,866,000 | 0.42% |
| Avidity Partners Management LP | 392,000 | $10,404,000 | 0.34% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 500,000 | $13,270,000 | 0.28% |
| Perceptive Advisors | 470,440 | $12,485,000 | 0.13% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 250,000 | $6,635,000 | 0.13% |